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Introduction {#sec001}
============

Polymorphism in the Rhesus factor, namely the existence of a large deletion in the RHD gene \[[@pone.0141362.ref001]\] in a substantial fraction of the human population, has been an evolutionary enigma since the discovery of this factor in the 1930's \[[@pone.0141362.ref002]--[@pone.0141362.ref005]\]. Theoretically, neither the RhD-negative allele can successfully spread in the RhD positive population nor the RhD-positive allele can spread in the RhD negative population \[[@pone.0141362.ref006],[@pone.0141362.ref007]\]. Before the introduction of prophylactic treatment in 1968, a positive frequency dependent selection systematically penalized the less abundant allele because lots of children of RhD-negative women in the mostly RhD-positive population as well as children of RhD- positive men in the mostly RhD-positive population were dying of hemolytic anemia. It has been suggested that this polymorphism can be stabilized when the disadvantage of carriers of the locally rarer allele is counterbalanced by higher viability of their heterozygote children or by another form of frequency-dependent selection \[[@pone.0141362.ref006]\]. In the past seven years, several studies have demonstrated that Rhesus positive and Rhesus negative subjects differ in resistance to the adverse effects of parasitic infections, aging, fatigue and smoking \[[@pone.0141362.ref007]--[@pone.0141362.ref013]\]. A study performed on 250 blood donors has further shown that the resistance to effects of toxoplasmosis is higher in Rhesus positive heterozygotes than in Rhesus positive homozygotes and substantially higher than in Rhesus negative homozogotes \[[@pone.0141362.ref007]\]. This is the first direct evidence for the role of selection in favour of heterozygotes in stabilization of the RHD gene polymorphism in human populations. Such a mechanism is reminiscent of widely known situations with polymorphism in genes associated with sickle cell anaemia in geographic regions with endemic malaria \[[@pone.0141362.ref014]\].

The results of previous studies suggest that RhD negative homozygotes could have a worse health status than RhD positive population consisting of RhD positive homozygotes and heterozygotes. These results, however, were obtained on either rather small or rather specific populations, e.g. military personnel \[[@pone.0141362.ref013]\] or pregnant women \[[@pone.0141362.ref012]\]. To obtain more reliable data about situation in more typical populations, we run a large questionnaire study in a population of healthy Czech and Slovak volunteers. Using an electronic questionnaire distributed with a Facebook-based snowball method \[[@pone.0141362.ref015]\], we have screened a population of 3,130 subjects for indices of various health problems as well as for incidences of 225 diseases and disorders.

Methods {#sec002}
=======

Ethics Statement {#sec003}
----------------

Only subjects older 18 years were invited and allowed to start the internet test. We erased data of 7 subjects who claimed to be younger as well as the data of all subjects who did not respond how old they were. The study, including the method of obtaining an electronic consent with a participation in the study (by pressing a particular button), was approved by the IRB of the Faculty of Science, Charles University (Komise pro práci s lidmi a lidským materiálem Přírodovědecké Fakulty Univerzity Karlovy)---No. 2014/21.

Subjects {#sec004}
--------

The subjects were invited to participate in the study using a Facebook-based snowball method \[[@pone.0141362.ref015]\] by posting an invitation to participate in "an experiment searching for associations between the blood group of a subject and his/her personality, performance, morphology and health" on the wall of the Facebook page "Guinea pigs" for Czech and Slovak nationals willing to take part in diverse evolutionary psychological experiments ([www.facebook.com/pokusnikralici](http://www.facebook.com/pokusnikralici)). The participants were informed about the aims of the study on the first page of the electronic questionnaire: "The subject of the present study is searching for associations between the blood group of a subject and his/her personality, performance, morphology and health. If you can check up on what your blood group is, please do it now. "They were also provided with the following information: "The questionnaire is anonymous and obtained data will be used exclusively for scientific purposes. Your cooperation in the project is voluntary and you can terminate it at any time by closing this web page. If you can check up on what your blood group is, please do it now. We need the data from subjects with all blood groups, not only from Rh negative subjects. Therefore, please share the link to this questionnaire with your friends, for example on Facebook. Press the "continue" button if you agree to your anonymous participation in the study". The share button was pressed by 480 participants, which resulted in obtaining data from 4,286 responders in total between 28.4. 2014--9.3. 2015. Data file is available as the [S1 File](#pone.0141362.s001){ref-type="supplementary-material"}.

Questionnaire {#sec005}
-------------

The anamnestic questionnaire was prepared by two medical doctors and was distributed as a Czech/English Qualtrics survey (<http://1url.cz/q05K>). It contained two categories of questions. The first of them monitored presence and intensity of general and specific health problems of responders. The responders were asked to subjectively rate of their allergic, cancer, digestive, fertility, genitourinary, heart, hematological, immunity, mental health, metabolic including endocrine, musculoskeletal, neurological, respiratory organs, sense organs, and sexual life problems using 6-points Likert.scales. The second group of questions tried to collect objective information reflecting the health status of responders. We asked the responders, for example, how many drugs prescribed by doctors they currently takes per day, how many of "different herbs, food supplements, multivitamins, superfoods etc." they currently take per day, how many times they used antibiotics during the past 365 days. We also provided the responders lists of about 250 disorders (separated to 15 categories) and asked them to tick which of them they were diagnosed with. The questionnaire contained, among others, also the following questions: "What is your Rh blood group?" with three options: a) I do not know / I am not sure, b) negative (this is the less frequent variant) c) positive (the more frequent variant). Implicitly, the answer a) (I do not know/I am not sure) was checked.

Statistical methods {#sec006}
-------------------

Before statistical analysis, suspicious data (too high or too short body height, too low or too high body mass or age, too short duration of the test etc.) were filtered out (26 cases). In the test, we also measured simple reaction times, operational, short-term and long-term memory, psychomotor performance, intelligence and personality profiles. However, here we have analyzed only data concerning health status.

SPSS v. 21. was used for all statistical tests. Ordinal and binary data were analyzed by partial Kendall´s correlation test \[[@pone.0141362.ref016],[@pone.0141362.ref017]\]. This test measures strength and significance of association between binary, ordinal and continuous data regardless of their distributions. This technique enabled us to control for one confounding variable, for example the age of a responder. The Excel sheet for computing partial Kendall's *Tau* and the significance between variables A and B after the variable C is controlled based on Kendall *Tau*´s AB, AC and BC. It is available here: <http://web.natur.cuni.cz/flegr/programy.php> (item no. 12) and in [S2 File](#pone.0141362.s002){ref-type="supplementary-material"}. Certain diseases have very different incidence in men and women. Also, some biological factors, including RhD phenotype, could have different impacts on men and women. Therefore, we performed all analyses for all responders and also separately for the male and female responders.

Results {#sec007}
=======

Descriptive statistics of data {#sec008}
------------------------------

Among 4,286 Czech and Slovak participants of a subsequent case-control study, 3,130 subjects (840 RhD positive men, 317 RhD negative men, 1,337 RhD positive women and 636 RhD negative women) provided information about their gender and RhD phenotype. RhD negative subjects, especially women, have higher motivation to care about, and to remember, their RhD phenotype. Therefore, the frequency of RhD negative subjects (30.4%) differed from the 16% general frequencies within the Czech and Slovak populations and also between men (27.4%) and women (32.2%). The mean age of RhD positive men (37.6, *S*.*D*. 13.5) was approximately the same as that of RhD negative men (37.7, *S*.*D*. 12.7), *t* ~*(1153)*~ = -0.10, *P* = 0.923. RhD positive women were younger (33.6, *S*.*D*. 11.9) than RhD negative women (35.2, *S*.*D*. 12.7), *t* ~*(1923)*~ = 2.74, *P* = 0.006. The numbers of men and women in the particular age strata were comparable, with the exception of the 21--30 age stratum, which consisted of 363 men and 842 women ([Fig 1](#pone.0141362.g001){ref-type="fig"}).

![Age distribution for male and female participants of a study.](pone.0141362.g001){#pone.0141362.g001}

Correlation of RhD phenotype with self-reported health problems (ordinal variables) {#sec009}
-----------------------------------------------------------------------------------

Twenty-two dependent variables (mostly ratings of particular health problems on a scale from 1--6, 1: "no problems at all", 6: "frequent or serious") were ordinal and had a highly skewed distribution. Therefore, the nonparametric partial Kendall's correlation test (which enables to control one confounding variable, here the age) was used to search for an association between the RhD phenotype and the intensity of fifteen categories of health problems (allergic, cancer, digestive, fertility, genitourinary, heart, hematological, immunity, mental health, metabolic including endocrine, musculoskeletal, neurological, respiratory organs, sense organs, and sexual life problems) and also another six health-related variables, namely the numbers of drugs prescribed by doctors that the subject currently takes per day, numbers of "different herbs, food supplements, multivitamins, superfoods etc." the subject currently takes per day, how many times the subject has used antibiotics during the past 365 days, how many times the subject was required to seek acute medical care for a serious illness (not injury) that lasted more than 3 days during the past 5 years, how many specialized medical doctors the subject had to regularly attend (not for prevention) at least once in the past two years, how often the subject felt tired (not after exertion, e.g. sports) and how often the subject has experienced a headache. The results showed that the RhD negative subjects had more serious health problems in 6 of 22 analyzed variables than the RhD positive subjects ([Table 1](#pone.0141362.t001){ref-type="table"}).

10.1371/journal.pone.0141362.t001

###### Difference in various health status related variables between RhD negative and RhD positive subjects.

![](pone.0141362.t001){#pone.0141362.t001g}

                         all      men           women                           
  ---------------------- -------- ------------- -------- ------------- -------- -------------
  allergic               0.018    0.153         0.016    0.444         0.012    0.450
  cancer                 0.008    0.514         -0.053   **0.012\***   0.031    **0.052**
  digestive              0.034    **0.008\***   -0.016   0.443         0.050    **0.002\***
  fertility              -0.009   0.475         0.045    **0.035\***   -0.042   **0.009\***
  genitourinary          0.006    0.628         -0.026   0.223         -0.003   0.844
  heart & vascular       0.031    **0.015\***   0.001    0.971         0.047    **0.003\***
  hematological          0.028    **0.028\***   -0.028   0.185         0.031    **0.053**
  immunity               0.034    **0.007\***   0.023    0.268         0.024    0.126
  metabolic              -0.006   0.672         -0.020   0.342         -0.017   0.296
  musculoskeletal        0.015    0.264         -0.039   **0.069**     0.035    **0.034\***
  mental health          0.013    0.322         0.049    **0.024\***   -0.012   0.460
  neurological           0.016    0.225         0.060    **0.005\***   -0.013   0.417
  respiratory org.       -0.003   0.798         -0.002   0.918         -0.008   0.613
  sense organs           -0.014   0.279         -0.033   0.120         -0.012   0.454
  sexual life            -0.012   0.369         -0.011   0.615         -0.007   0.649
  medicine/day           0.049    **0.000\***   0.047    **0.025\***   0.045    **0.004\***
  herbs/day              -0.001   0.942         0.045    **0.030\***   -0.039   **0.014\***
  antibiotics/year       0.014    0.269         -0.022   0.290         0.023    0.136
  acute care/5 years     0.002    0.883         0.016    0.429         -0.013   0.418
  doctors/2 years        0.018    0.162         -0.017   0.425         0.025    0.122
  tired (frequency)      0.026    **0.046\***   0.010    0.637         0.019    0.238
  headache (frequency)   0.013    0.321         0.024    0.264         -0.020   0.214

Number of responders varied between particular questions and was about 1,000 for men and 1,800 for women. Mostly significant effects of age on health status were controlled in present partial Kendall *Tau* test. Positivity of *Tau* indicates that RhD negative subjects have higher values of particular health related variables, i.e., a worse health status. Significant results (*P* \< 0.05) and trends (*P* \< 0.10) are printed in bold. Asterisks indicate results significant in two-sided tests. Values \< 0.0005 are coded as 0.000.

Association between RhD phenotype and incidence of particular diseases (binary variables) {#sec010}
-----------------------------------------------------------------------------------------

After rating each particular category of health problems, the subjects were asked to identify which specific disorders they suffered from on the lists of 225 disorders. They were also asked to identify which specialized medical doctors they had to visit regularly (not for prevention) at least once in the past two years from a list of 10 types of specialists. The associations were analyzed with the partial Kendall's *Tau* correlation test with age being a covariate. One hundred fifty four (154) of 225 diseases/disorders were reported by at least 10 subjects. Within this subset, 31 significant associations with RhD negativity (21 positive and 10 negative) were expressed in all subjects. In male subjects, the number of significant association was 35 (19 positive and 16 negative) while in female subjects the number of significant associations was 30 (18 positive and 12 negative). The expected number of false significant results for 462 statistical tests was not 96 but 23. For example, RhD negative men more often reported certain mental health disorders including panic disorders, antisocial personality disorders and attention deficits, ticks, fasciculation, thyroiditis, immunity disorders, allergies, especially skin allergies, excessive bleedings, anemia, osteoporosis, liver disease, infectious diseases and acute diarrhea diseases, while they less often reported gall bladder attacks, coeliac disease, maldigestion, malabsobtion, warts, some types of cancers and prostate hypertrophy. RhD negative women reported more frequently psoriasis, constipation and diarrheas, ischemic diseases, type 2 diabetes, some types of cancers, lymphatic nodes swelling, vitamin B deficiency, thrombosis, tonsil stones, too high sex desire, precocious puberty, urinary tract infections, scoliosis and they less often reported hearing loss, weight loss, hypoglycemia, glaucoma, fasciculation and warts. RhD negative subjects had to make more frequent visits to medical professionals specializing in otolaryngology (*P* = 0.021), psychiatry (*P* = 0.008), gynecology (*P* \< 0.001), and dermatology (*P* = 0.014) (the theoretical number of false positive results was 0.5). [Table 2](#pone.0141362.t002){ref-type="table"} shows the associations between RhD negativity and disease incidences while [Table 3](#pone.0141362.t003){ref-type="table"} shows the associations between RhD negativity and visiting specialized doctors.

10.1371/journal.pone.0141362.t002

###### Differences in incidences of particular disorders between RhD positive and RhD negative subjects.

![](pone.0141362.t002){#pone.0141362.t002g}

                                     All   Men   Women                                                                                                                   
  ---------------------------------- ----- ----- ------- ------ -------- ------------- ----- ----- ----- ----- -------- ------------- ----- ----- ------ ------ -------- -------------
  Pharyngitis                        294   591   600     1379   -0.030   **0.017\***   100   185   255   498   -0.012   0.570         194   406   345    881    -0.045   **0.004\***
  Bronchitis, pneumonia              686   199   1519    460    -0.009   0.476         233   52    602   151   -0.021   0.320         453   147   917    309    -0.009   0.558
  Rhinitis, tonsilitis               367   518   847     1132   0.015    0.240         134   151   362   391   0.010    0.630         233   367   485    741    0.010    0.513
  Ectoparasites, e.g. lice           738   147   1649    330    0.002    0.868         250   35    675   78    0.028    0.174         488   112   974    252    -0.018   0.253
  Scabies                            868   17    1930    49     -0.018   0.147         280   5     733   20    -0.026   0.203         588   12    1197   29     -0.014   0.378
  Helminthiasis                      844   41    1876    103    -0.012   0.325         272   13    723   30    0.013    0.545         572   28    1153   73     -0.027   **0.090**
  Acute diarrhea dis.                724   161   1679    300    0.040    **0.001\***   238   47    658   95    0.051    **0.014\***   486   114   1021   205    0.031    **0.046\***
  Acquired immunodef.                866   19    1935    44     -0.003   0.796         283   2     743   10    -0.026   0.202         583   17    1192   34     0.000    0.991
  Flu and flu-like virosis           297   588   632     1347   -0.013   0.312         87    198   228   525   -0.001   0.945         210   390   404    822    -0.014   0.381
  Borreliosis                        801   84    1807    172    0.011    0.391         264   21    694   59    -0.009   0.677         537   63    1113   113    0.016    0.297
  Other thick born dis               878   7     1962    17     -0.003   0.797         280   5     745   8     0.028    0.177         598   2     1217   9      -0.024   0.128
  Sexually transmit. dis.            870   15    1934    45     -0.018   0.142         280   5     738   15    -0.008   0.712         590   10    1196   30     -0.024   0.118
  Hepatitis A, E                     878   7     1955    24     -0.022   **0.083**     283   2     741   12    -0.035   **0.088**     595   5     1214   12     -0.012   0.448
  Hepatitis B                        879   6     1970    9      0.013    0.303         282   3     748   5     0.019    0.355         597   3     1222   4      0.012    0.452
  Herpes zoster                      832   53    1855    124    -0.007   0.553         272   13    708   45    -0.028   0.181         560   40    1147   79     0.000    0.978
  Herpes, oral or genital            623   262   1410    569    0.008    0.531         218   67    559   194   -0.023   0.259         405   195   851    375    0.017    0.275
  Meningoencephalitis                872   13    1960    19     0.021    **0.087**     281   4     747   6     0.027    0.185         591   9     1213   13     0.017    0.279
  Inflamm. of middle ear             618   267   1400    579    0.011    0.379         212   73    565   188   0.007    0.739         406   194   835    391    0.007    0.637
  Eye infections                     784   101   1739    240    -0.009   0.467         261   24    699   54    0.021    0.309         523   77    1040   186    -0.030   **0.058**
  Other infectious dis.              823   62    1874    105    0.034    **0.007\***   265   20    719   34    0.050    **0.015\***   558   42    1155   71     0.024    0.131
  Skin mycosis                       686   199   1558    421    0.013    0.310         246   39    626   127   -0.040   **0.055**     440   160   932    294    0.028    **0.076**
  Bacterial skin infect.             822   63    1851    128    0.013    0.285         265   20    704   49    0.009    0.654         557   43    1147   79     0.017    0.288
  Warts                              600   285   1244    735    -0.045   **0.000\***   194   91    479   274   -0.041   **0.048\***   406   194   765    461    -0.047   **0.003\***
  Lymphatic modes swelling           840   45    1883    96     0.007    0.588         275   10    727   26    0.001    0.943         565   35    1156   70     0.006    0.712
  Mononucleosis                      778   107   1728    251    -0.007   0.587         262   23    690   63    -0.004   0.831         516   84    1038   188    -0.016   0.312
  Tonsil stones                      657   183   1534    330    0.047    **0.000\***   235   36    631   96    0.001    0.970         422   147   903    234    0.057    **0.000\***
  Skin allergy                       646   224   1482    462    0.022    **0.075**     230   52    633   104   0.054    **0.010\***   416   172   849    358    -0.004   0.810
  Food allergy                       765   105   1698    246    -0.007   0.577         259   23    670   67    -0.014   0.491         506   82    1028   179    -0.011   0.495
  Respiratory allergy                535   335   1193    751    0.001    0.935         174   108   448   289   -0.008   0.716         361   227   745    462    0.007    0.673
  Other allergies                    806   64    1814    130    0.011    0.361         260   22    699   38    0.050    **0.016\***   546   42    1115   92     -0.011   0.493
  Autoimmunity                       803   50    1815    94     0.019    0.127         269   8     709   13    0.034    0.103         534   42    1106   81     0.007    0.682
  Rheumatoid arthritis               831   22    1880    29     0.033    **0.008\***   271   6     713   9     0.033    0.117         560   16    1167   20     0.031    **0.052**
  Haematological autoimmunity dis.   848   5     1898    11     0.000    0.985         276   1     718   4     -0.012   0.558         572   4     1180   7      0.006    0.723
  Thyroiditis                        781   72    1789    120    0.038    **0.002\***   269   8     711   11    0.045    **0.034\***   512   64    1078   109    0.027    **0.085**
  Immunodeficiency                   813   40    1824    85     0.006    0.651         272   5     709   13    0.000    0.998         541   35    1115   72     0.001    0.964
  Bechterew´s dis.                   847   6     1902    7      0.022    **0.088**     275   2     719   3     0.019    0.367         572   4     1183   4      0.023    0.141
  Other immunolog. dis.              796   57    1830    79     0.054    **0.000\***   262   15    707   15    0.088    **0.000\***   534   42    1123   64     0.037    **0.021\***
  Psoriasis                          829   24    1867    42     0.017    0.177         268   9     698   24    -0.002   0.919         561   15    1169   18     0.035    **0.027\***
  Stomach or duodenal ulcer          810   34    1840    62     0.017    0.178         264   11    704   25    0.013    0.544         546   23    1136   37     0.020    0.212
  Chronic gastritis                  827   17    1845    57     -0.030   **0.018\***   272   3     714   15    -0.033   0.112         555   14    1131   42     -0.033   **0.038\***
  Liver disease                      806   38    1841    61     0.031    **0.014\***   263   12    713   16    0.058    **0.006\***   543   26    1128   45     0.016    0.303
  Diarrheas                          647   197   1496    406    0.027    **0.034\***   234   41    594   135   -0.041   **0.050\***   413   156   902    271    0.055    **0.001\***
  Constipation                       701   143   1638    264    0.042    **0.001\***   261   14    689   40    -0.008   0.719         440   129   949    224    0.044    **0.006\***
  Maldigestion, food intolerance     733   111   1646    256    -0.002   0.845         261   14    663   66    -0.065   **0.002\***   472   97    983    190    0.013    0.405
  Malabsoption                       822   22    1864    38     0.019    0.137         270   5     723   6     0.043    **0.042\***   552   17    1141   32     0.006    0.707
  Bulimia, anorexia                  824   20    1846    56     -0.015   0.247         275   275   729   729   0.000    1.000         549   20    1117   56     -0.027   **0.086**
  Flatulence                         676   168   1559    343    0.023    **0.076**     235   40    621   108   -0.003   0.875         441   128   938    235    0.029    **0.075**
  Weight loss                        826   18    1846    56     -0.021   **0.094**     272   3     723   6     0.014    0.521         554   15    1123   50     -0.038   **0.017\***
  Other digestive dis.               817   27    1844    58     0.004    0.764         266   9     710   19    0.018    0.393         551   18    1134   39     -0.005   0.764
  Pyrosis reflux                     682   162   1555    347    0.010    0.453         224   51    598   131   0.006    0.774         458   111   957    216    0.010    0.519
  Gall bladder attack                812   32    1812    90     -0.023   **0.065**     272   3     704   25    -0.064   **0.002\***   540   29    1108   65     -0.014   0.376
  Coeliac disease                    834   10    1877    25     -0.005   0.677         275   0     723   6     -0.048   **0.024\***   559   10    1154   19     0.005    0.762
  Hypertensive disease               808   18    1816    48     -0.016   0.222         261   4     689   21    -0.042   **0.049\***   547   14    1127   27     -0.002   0.910
  Ischaemic disease                  819   7     1856    8      0.024    **0.067**     264   1     704   6     -0.026   0.229         555   6     1152   2      0.059    **0.000\***
  Other heart dis.                   801   25    1791    73     -0.022   **0.091**     255   10    682   28    -0.004   0.855         546   15    1109   45     -0.031   **0.055**
  Excessive bleeding                 816   10    1848    16     0.016    0.203         263   2     709   1     0.049    **0.021\***   553   8     1139   15     0.004    0.792
  Thrombosis                         815   11    1847    17     0.018    0.171         264   1     699   11    -0.048   **0.024\***   551   10    1148   6      0.060    **0.000\***
  Atrial fibrilation                 824   2     1856    8      -0.015   0.254         265   0     706   4     -0.039   **0.065**     559   2     1150   4      0.000    1.000
  Arrhythmia, non serious            754   72    1700    164    -0.003   0.821         249   16    657   53    -0.025   0.237         505   56    1043   111    0.003    0.865
  Arrythmia, serious                 822   4     1856    8      0.002    0.875         264   1     705   5     -0.020   0.358         558   3     1151   3      0.020    0.206
  Anemia                             712   103   1667    184    0.039    **0.002\***   257   9     701   11    0.058    **0.007\***   455   94    966    173    0.021    0.186
  High leukocytes level              803   12    1827    24     0.006    0.630         261   5     705   7     0.036    **0.092**     542   7     1122   17     -0.010   0.541
  Low leukocytes level               805   10    1831    20     0.007    0.604         262   4     705   7     0.022    0.299         543   6     1126   13     -0.002   0.910
  Other problems with leucocytes     812   3     1841    10     -0.012   0.352         266   0     707   5     -0.044   **0.039\***   546   3     1134   5      0.007    0.679
  Other blood diseases               793   22    1804    47     0.004    0.734         260   6     690   22    -0.022   0.295         533   16    1114   25     0.021    0.188
  High platelets level               810   5     1844    7      0.016    0.211         264   2     709   3     0.021    0.334         546   3     1135   4      0.014    0.383
  Low platalets level                809   6     1829    22     -0.020   0.116         265   1     706   6     -0.025   0.251         544   5     1123   16     -0.021   0.193
  Excessive bleeding                 768   47    1767    84     0.027    **0.038\***   263   3     707   5     0.021    0.327         505   44    1060   79     0.019    0.231
  Accented blood clotting            806   9     1815    36     -0.029   **0.023\***   265   1     703   9     -0.039   **0.065**     541   8     1112   27     -0.029   **0.078**
  Iron deficiency                    706   109   1636    215    0.025    **0.052**     261   5     698   14    -0.003   0.888         445   104   938    201    0.014    0.376
  Lymphatic nodes swelling           799   16    1828    23     0.027    **0.034\***   265   1     707   5     -0.019   0.375         534   15    1121   18     0.038    **0.018\***
  Vitamin B12 deficiency             794   21    1822    29     0.034    **0.008\***   265   1     706   6     -0.025   0.240         529   20    1116   23     0.048    **0.003\***
  Type1 diabetes                     793   6     1805    9      0.015    0.237         259   3     699   3     0.040    **0.060**     534   3     1106   6      0.001    0.939
  Crohn\'s disease                   794   5     1808    6      0.020    0.118         261   1     700   2     0.008    0.723         533   4     1108   4      0.025    0.132
  Immunodeficiency                   785   14    1776    38     -0.011   0.387         258   4     696   6     0.030    0.167         527   10    1080   32     -0.031   **0.058**
  Type 2 diabetes                    786   13    1787    27     0.002    0.903         259   3     685   17    -0.042   **0.054**     527   10    1102   10     0.036    **0.028\***
  Hypothyroidism                     724   75    1674    140    0.028    **0.033\***   260   2     694   8     -0.016   0.449         464   73    980    132    0.022    0.181
  Hyperthyroidism                    791   8     1796    18     0.000    0.988         262   0     701   1     -0.020   0.358         529   8     1095   17     -0.002   0.882
  Inborn metabolic dis.              795   4     1805    9      0.001    0.963         262   0     698   4     -0.039   **0.069**     533   4     1107   5      0.019    0.254
  Obesity                            720   79    1630    184    -0.008   0.528         238   24    649   53    0.025    0.241         482   55    981    131    -0.031   **0.062**
  Hypoglycemia                       794   5     1791    23     -0.028   **0.030\***   260   2     698   4     0.011    0.594         534   3     1093   19     -0.047   **0.004\***
  Osteoporosis                       785   14    1786    28     0.005    0.716         261   1     702   0     0.052    **0.015\***   524   13    1084   28     -0.009   0.579
  Delayed puberty                    792   7     1797    17     -0.002   0.859         261   1     692   10    -0.043   **0.044\***   531   6     1105   7      0.027    0.103
  Precocious puberty                 793   6     1807    7      0.023    **0.072**     262   0     700   2     -0.028   0.196         531   6     1107   5      0.037    **0.024\***
  Amenorrhea                         788   11    1793    21     0.010    0.424         262   262   702   702   0.000    1.000         526   11    1091   21     0.007    0.669
  Other metabolic dis.               773   26    1759    55     0.006    0.664         258   4     691   11    -0.001   0.950         515   22    1068   44     0.002    0.909
  Melanoma and other skin cancer     828   5     1875    10     0.003    0.793         273   0     715   6     -0.048   **0.022\***   555   5     1160   4      0.034    **0.032\***
  Breast cancer                      831   2     1876    9      -0.019   0.143         273   273   721   721   0.000    1.000         558   2     1155   9      -0.028   **0.084**
  Cervix uteri cancer                821   12    1868    17     0.023    **0.067**     273   273   721   721   0.000    1.000         548   12    1147   17     0.023    0.161
  Other cancer diseases              824   9     1874    11     0.026    **0.042\***   273   0     713   8     -0.056   **0.009\***   551   9     1161   3      0.075    **0.000\***
  Urinary tract infections           606   184   1473    326    0.060    **0.000\***   245   20    657   45    0.019    0.364         361   164   816    281    0.058    **0.000\***
  Nephrosis, glumerulonephritis      779   11    1778    21     0.009    0.501         264   1     696   6     -0.026   0.234         515   10    1082   15     0.020    0.233
  Bladder infection, cystitis        725   65    1666    133    0.014    0.269         261   4     692   10    0.003    0.896         464   61    974    123    0.005    0.782
  Prostate hypertrophy               787   3     1773    26     -0.051   **0.000\***   262   3     676   26    -0.070   **0.001\***   525   525   1097   1097   0.000    1.000
  Gynaecological infections          644   146   1518    281    0.038    **0.004\***   265   0     700   2     -0.028   0.197         379   146   818    279    0.026    0.116
  Cervical precancerosis or cancer   778   12    1774    25     0.005    0.725         265   265   702   702   0.000    1.000         513   12    1072   25     -0.002   0.923
  Obstretic complications            760   30    1743    56     0.015    0.262         265   265   702   702   0.000    1.000         495   30    1041   56     0.006    0.737
  Recurrent abortions                778   12    1773    26     0.001    0.943         265   265   702   702   0.000    1.000         513   12    1071   26     -0.007   0.659
  Kidney stones                      778   12    1756    43     -0.030   **0.024\***   261   4     688   14    -0.017   0.430         517   8     1068   29     -0.037   **0.024\***
  Other genitourinary dis.           771   19    1759    40     0.006    0.669         263   2     682   20    -0.063   **0.004\***   508   17    1077   20     0.045    **0.007\***
  Glaucoma                           798   4     1793    23     -0.036   **0.006\***   262   2     696   7     -0.011   0.606         536   2     1097   16     -0.050   **0.002\***
  Cataracts, clouding of the lens    793   9     1796    20     -0.002   0.880         260   4     693   10    0.002    0.920         533   5     1103   10     -0.002   0.905
  Refractive errors                  438   364   982     834    -0.006   0.646         161   103   422   281   -0.009   0.661         277   261   560    553    -0.013   0.436
  Hearing loss                       773   29    1717    99     -0.041   **0.002\***   251   13    661   42    -0.021   0.327         522   16    1056   57     -0.051   **0.002\***
  Macular degeneration               791   11    1797    19     0.013    0.319         261   3     694   9     -0.006   0.785         530   8     1103   10     0.024    0.144
  Strabismus                         786   16    1777    39     -0.006   0.669         258   6     685   18    -0.009   0.687         528   10    1092   21     -0.001   0.930
  Sense of smell problems            789   13    1765    51     -0.037   **0.005\***   258   6     674   29    -0.045   **0.037**     531   7     1091   22     -0.026   0.117
  Sense of taste prob.               800   2     1807    9      -0.018   0.167         264   0     699   4     -0.040   **0.065**     536   2     1108   5      -0.006   0.706
  Ringing in the ears                741   61    1671    145    -0.010   0.465         239   25    626   77    -0.023   0.285         502   36    1045   68     0.008    0.624
  Other sense organs dis.            767   35    1745    71     0.011    0.415         254   10    671   32    -0.016   0.445         513   25    1074   39     0.027    0.100
  Sense of motion problems           772   30    1757    59     0.011    0.403         260   4     689   14    -0.016   0.447         512   26    1068   45     0.015    0.355
  Amblyopia, lazy eye                768   34    1728    88     -0.014   0.269         256   8     664   39    -0.053   **0.014\***   512   26    1064   49     0.009    0.595
  Extremity neuropathy               802   8     1822    24     -0.015   0.242         265   2     702   9     -0.023   0.281         537   6     1120   15     -0.011   0.499
  Multiple sclerosis                 805   5     1840    6      0.021    0.108         266   1     710   1     0.023    0.280         539   4     1130   5      0.018    0.261
  Epilepsy                           805   5     1830    16     -0.013   0.319         264   3     706   5     0.021    0.335         541   2     1124   11     -0.032   **0.052**
  Migraine                           627   183   1450    396    0.014    0.287         231   36    620   91    0.009    0.676         396   147   830    305    0.003    0.850
  Other neurologic dis.              793   17    1812    34     0.008    0.555         263   4     703   8     0.015    0.484         530   13    1109   26     0.001    0.959
  Stuttering                         799   11    1819    27     -0.003   0.812         263   4     699   12    -0.006   0.764         536   7     1120   15     0.001    0.962
  Tics                               780   30    1771    75     -0.007   0.601         252   15    685   26    0.045    **0.036\***   528   15    1086   49     -0.036   **0.027\***
  Muscle twitch, fasciculation       753   57    1705    141    -0.010   0.443         243   24    666   45    0.047    **0.029\***   510   33    1039   96     -0.041   **0.011\***
  Cramps                             746   64    1700    146    0.000    0.971         253   14    663   48    -0.027   0.201         493   50    1037   98     0.010    0.543
  Unipolar depressive disorders      765   31    1742    78     -0.009   0.469         252   9     682   18    0.024    0.274         513   22    1060   60     -0.028   **0.084**
  Bipolar disorder                   786   10    1800    20     0.007    0.587         259   2     691   9     -0.022   0.317         527   8     1109   11     0.023    0.169
  Anxiety disorders                  745   51    1720    100    0.019    0.136         251   10    674   26    0.003    0.879         494   41    1046   74     0.021    0.200
  Alcohol use disorders              787   9     1803    17     0.009    0.509         256   5     687   13    0.002    0.938         531   4     1116   4      0.027    **0.096**
  Drug use disorders                 788   8     1797    23     -0.011   0.396         258   3     688   12    -0.020   0.347         530   5     1109   11     -0.002   0.901
  Post traumatic disorder            785   11    1787    33     -0.016   0.221         259   2     692   8     -0.017   0.437         526   9     1095   25     -0.019   0.239
  Obsessive compulsive dis.          783   13    1783    37     -0.012   0.338         257   4     682   18    -0.030   0.158         526   9     1101   19     0.001    0.973
  Panic disorder                     767   29    1772    48     0.027    **0.035\***   254   7     690   10    0.043    **0.048\***   513   22    1082   38     0.017    0.304
  Insomnia primary                   727   69    1655    165    -0.005   0.685         241   20    658   42    0.030    0.158         486   49    997    123    -0.027   0.103
  Learning disability                767   29    1761    59     0.011    0.389         250   11    679   21    0.031    0.156         517   18    1082   38     0.001    0.964
  Borderline personality disorder    787   9     1804    16     0.013    0.325         259   2     696   4     0.011    0.608         528   7     1108   12     0.013    0.446
  Antisocial personality disorder    787   9     1802    18     0.008    0.554         253   8     691   9     0.061    **0.005\***   534   1     1111   9      -0.034   **0.037\***
  Attention deficit, hyperactivity   772   24    1779    41     0.024    **0.068**     247   14    685   15    0.084    **0.000\***   525   10    1094   26     -0.012   0.466
  Other mental health dis.           769   27    1777    43     0.030    **0.021\***   252   9     692   8     0.078    **0.000\***   517   18    1085   35     0.007    0.691
  Erectile dysfunction               783   31    1746    83     -0.021   0.105         235   31    631   82    0.000    0.993         548   0     1115   1      -0.018   0.260
  Too low sex appetency              654   160   1473    356    0.001    0.930         231   35    622   91    0.004    0.834         423   125   851    265    -0.013   0.428
  Too high sex appetency             749   65    1695    134    0.012    0.368         228   38    612   101   0.002    0.933         521   27    1083   33     0.052    **0.001\***
  Too low sex potency                809   5     1811    18     -0.020   0.123         262   4     697   16    -0.024   0.259         547   1     1114   2      0.000    0.994
  Quality of sex                     724   90    1628    201    0.000    0.999         244   22    644   69    -0.022   0.304         480   68    984    132    0.007    0.690
  Other sexuological dis.            791   23    1762    67     -0.021   0.101         256   10    680   33    -0.018   0.392         535   13    1082   34     -0.021   0.209
  Paraphilias (mild)                 942   11    2157    20     0.011    0.349         312   5     830   10    0.015    0.433         630   6     1327   10     0.011    0.484
  Spondylosis, spondylitis           774   9     1772    18     0.004    0.733         256   2     689   8     -0.017   0.434         518   7     1083   10     0.016    0.338
  Backbone pain                      517   266   1168    622    -0.010   0.430         184   74    498   199   0.000    0.987         333   192   670    423    -0.025   0.139
  Osteoporosis                       765   18    1764    26     0.027    **0.037\***   256   2     696   1     0.050    **0.022\***   509   16    1068   25     0.017    0.292
  Rheumatoid arthritis               758   25    1741    49     0.010    0.467         249   9     673   24    0.000    0.993         509   16    1068   25     0.019    0.258
  Scoliosis                          646   137   1538    252    0.046    **0.000\***   229   29    624   73    0.012    0.583         417   108   914    179    0.054    **0.001\***
  Scheuermann\'s disease             774   9     1762    28     -0.017   0.189         254   4     681   16    -0.024   0.274         520   5     1081   12     -0.007   0.656
  Other musculosceletal dis.         758   25    1745    45     0.020    0.127         252   6     680   17    -0.003   0.878         506   19    1065   28     0.031    **0.059**
  Osteoarthrosis                     742   41    1706    84     0.008    0.555         243   15    666   31    0.027    0.209         499   26    1040   53     -0.004   0.825
  Bronchitis                         721   62    1634    156    -0.016   0.228         246   12    644   53    -0.054   **0.013\***   475   50    990    103    -0.002   0.892
  Asthma                             701   82    1577    213    -0.019   0.139         231   27    626   71    0.005    0.829         470   55    951    142    -0.035   **0.035\***
  Recurrent infections               699   84    1585    205    -0.012   0.345         240   18    637   60    -0.027   0.206         459   66    948    145    -0.013   0.430
  Other respiratory dis.             756   27    1734    56     0.007    0.569         248   10    683   14    0.053    **0.015\***   508   17    1051   42     -0.016   0.330

Numbers of RhD negative subjects without particular disorders, RhD negative subjects with particular disorders, RhD positive subjects without particular disorders, RhD positive subjects with particular disorders, partial Kendall´s Tau and statistical significance, respectively, are shown in six columns of each section. The effect of age on health status was controlled in partial Kendall's correlation (non-parametric) test. Positive Tau corresponds to a positive association and negative B to a negative association of RhD negativity with incidence of particular disorder. Significant results (p \< 0.05) and trends (p \< 0.10) are printed in bold. Asterisks indicate results significant in two-sided tests. p values \< 0.0005 are coded as 0.000. The effect size is shown as Tau.
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###### Differences between RhD positive and RhD negative participants in specialised medical doctors the subject had to regularly visit at least once in the past two years.

![](pone.0141362.t003){#pone.0141362.t003g}

                      RhD-V-   RhD-V+   RhD+V-      RhD+V+   *tau*    *p*
  ------------------- -------- -------- ----------- -------- -------- -------------
                                        **All**                       
  Internal medicine   710      101      1651        213      0.011    0.400
  Otolaryngology      720      91       1690        174      0.030    **0.021\***
  Neurology           747      64       1729        135      0.010    0.419
  Psychiatry          746      65       1751        113      0.036    **0.006\***
  Gynecology          641      170      1539        325      0.045    **0.000\***
  Surgery             766      45       1740        124      -0.020   0.114
  Infectology         797      14       1838        26       0.013    0.318
  Orthopedy           705      106      1643        221      0.017    0.188
  Dermatology         680      131      1602        262      0.029    **0.023\***
  Other Doctors       610      201      1357        507      -0.025   **0.051**
                                        **Men**                        
  Internal medicine   241      30       617         92       -0.028   0.197
  Otolaryngology      242      29       646         63       0.028    0.194
  Neurology           252      19       669         40       0.025    0.238
  Psychiatry          254      17       686         23       0.069    **0.001\***
  Gynecology          270      1        707         2        0.007    0.738
  Surgery             249      22       649         60       -0.006   0.792
  Infectology         266      5        691         18       -0.020   0.341
  Orthopedy           244      27       633         76       -0.012   0.585
  Dermatology         240      31       626         83       -0.003   0.872
  Other Doctors       223      48       556         153      -0.044   **0.040\***
                               ** **    **Women**   ** **              
  Internal medicine   469      71       1034        121      0.034    **0.038\***
  Otolaryngology      478      62       1044        111      0.031    **0.057**
  Neurology           495      45       1060        95       0.001    0.969
  Psychiatry          492      48       1065        90       0.017    0.308
  Gynecology          371      169      832         323      0.037    **0.024\***
  Surgery             517      23       1091        64       -0.025   0.124
  Infectology         531      9        1147        8        0.047    **0.004\***
  Orthopedy           461      79       1010        145      0.030    **0.069**
  Dermatology         440      100      976         179      0.042    **0.010\***
  Other Doctors       387      153      801         354      -0.023   0.155

Columns 2--5 show numbers of RhD- or RhD+ subjects that had to (V+) and had not to (V-) visit a doctor of particular specialisation within the past 2 years. Columns 6 and 7 show *Tau* and *P* computed with partial Kendall´s correlation between two binary variables, i.e. the RhD phenotype and the Visiting doctor, controlled for the confounding variable age of a subject. Positivity of *Tau* indicates that RhD negative subjects have had to more frequently visit a doctor of particular specialization. Significant results (*P* \< 0.05) and trends (*P* \< 0.10) are printed in bold. Asterisks indicate results significant in two-sided tests. Values \< 0.0005 are coded as 0.000.

Discussion {#sec011}
==========

The RhD negative subjects expressed many indices of a worse health status. Men, women or both sexes reported more frequent allergic, digestive, heart, hematological, immunity, mental health and neurological problems. They also reported the usage of more drugs prescribed by doctors per day, attended more specialized doctors, namely, dermatologists, gynecologists, internal medicine doctors, neurologists, and psychiatrists (men) in the past two years, a higher frequency of headaches and being tired more often than RhD positive subjects. Incidence of various diseases and disorders also differed between RhD negative and RhD positive subjects, mostly being higher in the former.

RhD negative subjects have increased the risk of developing of certain heart diseases, respiratory diseases and some immunity and autoimmunity related diseases, for example rheumatoid arthritis. The general pattern suggests that RhD negative subjects could have problems with autoimmunity, could be more resistant to infections of viral origin and could be less resistant to infections of bacterial origin.

The mechanism of the effect of the RhD phenotype on human health status is not clear. RhD protein together with strongly homologous RhCE protein and with also homologous RhAG glycoprotein are all components of a membrane complex of which the function is not quite clear. It is most probably involved in NH~3~ transport and possibly also in CO~2~ transport \[[@pone.0141362.ref018],[@pone.0141362.ref019]\]. This complex is associated with spectrin-based cytoskeleton and therefore plays an important role in maintaining the typical shape (biconcave discoid) of human erythrocytes \[[@pone.0141362.ref020]\]. The biological functions of complexes containing the RhD protein are unknown. However, they might be involved in NH~3~ /NH~4~ ^+^ detoxification of organs. Ammonia, the product of protein catabolism is extremely toxic, especially for brain cells and must be quickly removed from the sensitive organs. It was observed that the concentration of ammonium is three times higher in red cells than in plasma \[[@pone.0141362.ref020]\] and it was further suggested that the RhD containing complex plays a key role in its capturing and its transport to the kidneys and the liver \[[@pone.0141362.ref020]\]. It was also suggested that the complex might participate in intracellular pH regulation \[[@pone.0141362.ref020]\] and consequently also in the regulation of local oxygen tension. It was suggested that RhD-negativity-associated anoxia in certain parts of the nervous system could be responsible for physiological (and also behavioral) effects of the RhD phenotype \[[@pone.0141362.ref021]\]. The variation of the oxygen tension in various organs and tissues could, of course, influence also other biological functions, including the functions of the immune system. This could explain why RhD negativity seems to be associated with neurological, mental health and immunological disorders. The probable roles of the RhD-containing complex in keeping the normal morphology and adhesiveness of red cells (for review see \[[@pone.0141362.ref020]\]) could be responsible for the observed associations of RhD negativity with some haematological and inflammation-related diseases, including arthritis.

Limitations and strength of present study: Using very effective Facebook-based snow-ball method we obtained data from a large number of subjects. However, most of them were relatively young people (mean age was 35.4). Most of the diseases and disorders with the largest public health impact (but possibly not the largest economic impact) start at a higher age in developed European countries such as the Czech and Slovak Republics. This can largely distort the whole picture of the RhD negativity impacts on public health. Future studies (which could be easily done in countries with available national databases of medical records of all citizens) should aim to recruit middle age and senior subjects. Our study compared the health status of RhD negative subjects (16% in general population of Czech and Slovak Republics) with RhD positive subjects, i.e., with the health status of mixed population of RhD positive homozygotes (36% of the general populations within the Czech and Slovak Republics) and heterozygotes (48% the general populations in the Czech and Slovak Republics). The results of the published case-control studies on the effects of the RhD genotype on psychomotor performance \[[@pone.0141362.ref022],[@pone.0141362.ref023]\], as well as the heterozygote advantage hypothesis, however, suggest that the health status of RhD positive homozygotes and heterozygotes differs. In further studies concentrated on particular disorders, smaller populations of subjects should be RhD genotyped using molecular biology techniques and then the health status of all three RhD genotypes have to be compared. In the present study, the health status data were collected using a questionnaire. This enabled to study of the effects of the RhD phenotypes on rarer disorders using a large population sample. Of course, more precise and more detailed data could be obtained from medical records. Primarily, we have run the study to confirm or disprove the alarming results of a previous small scale studies performed on non-typical populations. However, we had no *a priory* hypotheses which health-related variables should correlate with RhD phenotype or which disorders should occur more frequently in RhD negative subjects. Therefore, the present study had a more or less explorative character. Hence, we have reported the results of statistical tests without formal correction to multiple tests. It should be noted, however, that, for example, we have obtained 41% positive results for the ordinal health status variables and 20% positive results for binary health status variables. Theoretically, only 5% of false positive results should be expected in multiple tests. The main strength of the present study is the absence of any sieve effect, which could result in publication bias in other types of studies. Positive results of particularly observational or experimental studies and partly also meta-analytic studies, could be an artefact of intentional or unintentional "cherry-picking"; i.e. preferential or even exclusive publication of positive results. In our study we have searched for the effects of the RhD phenotype on all diseases and all disorders having high enough incidences in the Czech population (n = 154) and we have reported all, both positive and negative results.

Conclusions {#sec012}
===========

Some of the associations observed the present study were relatively strong and some of them concerned rather frequent disorders. Therefore, the total impact of frequency of RhD negative homozygotes in the general population on public health could be large.

The aim of the present study was to search for indices of validity of the heterozygote advantage hypothesis, namely for the indices of impaired health status of RhD negative subjects. It must be reminded, however, that the observed specific disease burden of the RhD negative subpopulation is in an agreement with predictions of this hypothesis but does not prove its validity. The higher disease burden in RhD negative homozygotes could be compensated either by increased fitness of heterozygotes (heterozygote advantage hypothesis) or by still unknown selection pressure in favor of RhD negative subjects. In this context, the shorter reaction times of RhD negative, *Toxoplasma*-free blood donors \[[@pone.0141362.ref007]\] and university students \[[@pone.0141362.ref008]\] and higher intelligence in RhD negative, *Toxoplasma*-infected soldiers \[[@pone.0141362.ref011]\] should be remembered. It could be speculated to what extent the highly uneven distributions of RHD minus alleles in world populations might be the result of a founder event and a gene flow \[[@pone.0141362.ref024]\] and to what extent it is also modulated by specific selection pressures caused by differences in the geographical distribution of a disease or diseases.

Supporting Information {#sec013}
======================
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